Vulvar Neoplasms: Clinical Trials

36 trials for Vulvar Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

23 completed, 8 recruiting, 2 terminated, 2 unknown. 36 Phase 1, 9 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 136Completed 23, Recruiting 8, Terminated 2, Unknown 2, Not yet recruiting 1
Phase 29Recruiting 5, Completed 2, Not yet recruiting 1, Terminated 1

Follow Vulvar Neoplasms: new trials by email Literature Review of Vulvar Neoplasms trials Research Report on Vulvar Neoplasms

Trials (filtered) newest first · largest first

All 36 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
E7 TCR-T cells, Aldesleukin - HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma
Phase 1 / Phase 2RecruitingChristian Hinrichs152025-08-112026-10-28
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
YH32364 - EGFR Overexpression, Locally Advanced Solid Tumor
Phase 1 / Phase 2RecruitingYuhan Corporation802025-06-122026-06-10
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Carbon Nanoparticle-Loaded Iron [CNSI-Fe], Carbon Nanoparticle-Loaded Iron - Tumor, Solid, Lung Cancer
Phase 1 / Phase 2RecruitingSichuan Enray Pharmaceutical Sciences Company542024-11-122026-02-25
Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma
SCG142, Cyclophosphamide, Fludarabine - HPV-Related Squamous Cell Carcinoma, HPV-Related Cervical Squamous Cell Carcinoma
Phase 1 / Phase 2Not yet recruitingSCG Cell Therapy Pte. Ltd.662024-10-012024-07-17
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
INCB099280, axitinib - Advanced Solid Tumors
Phase 1 / Phase 2TerminatedIncyte Corporation52024-04-162026-06-04
HRYZ-T101 Injection for HPV18 Positive Solid Tumor
HRYZ-T101 Injection, Fludarabine + Cyclophosphamide - Cervical Cancer, Head and Neck Squamous Cell Carcinoma
Phase 1RecruitingHRYZ Biotech Co.322023-11-012024-02-02
SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas
SCG142 TCR-T cells - Human Papillomavirus Associated Carcinomas, Cervical Cancer
Phase 1RecruitingThe Affiliated Hospital of Qingdao University182023-08-022024-08-09
HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor
Fludarabine + Cyclophosphamide, HRYZ-T101 TCR-T Cell - Cervical Cancer, Head and Neck Squamous Cell Carcinoma
Phase 1UnknownHRYZ Biotech Co.172023-03-212024-02-02
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere) - Advanced Solid Tumors, Genital Neoplasm, Female
Phase 1 / Phase 2RecruitingMarengo Therapeutics, Inc.3662023-01-042026-08-11
Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor
CNSI-Fe(II) 30 mg, CNSI-Fe(II) 60 mg, CNSI-Fe(II) 90 mg - Advanced Solid Tumor, Lung Cancer
Phase 1CompletedSichuan Enray Pharmaceutical Sciences Company192022-11-172025-08-03
A Study for Assessing the Efficacy and Safety of Tetrahydrobiopterin in Radiation-Induced Skin Injury
Tetrahydrobiopterin - Radiation-Induced Dermatitis
Phase 1UnknownWest China Second University Hospital452022-03-012022-02-28
Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid
Stimotimagene copolymerplasmid, Ganciclovir - Sarcoma, Melanoma
Phase 1CompletedGene Surgery LLC212022-01-012024-07-01
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Atezolizumab, Tivozanib - Bile Duct Cancer, Gall Bladder Cancer
Phase 1 / Phase 2RecruitingUniversity of Florida292021-12-072026-07-13
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
Bintrafusp Alfa, PDS01ADC, Entinostat - Oropharyngeal Cancer, Neck Cancer
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)552021-10-052026-09-22
Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery
Cisplatin, External Beam Radiation Therapy, Nelfinavir - Stage II Vulvar Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8
Phase 1RecruitingM.D. Anderson Cancer Center252020-08-072026-11-10
A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli), Recombinant nonavalent Human Papillomavirus (Types 6,11,16,18,31,33,45,52,58) Vaccine - Human Papillomavirus Infection
Phase 1CompletedBeijing Health Guard Biotechnology, Inc1602019-09-012023-01-17
Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
9-valent HPV Recombinant Vaccine, Placebo - Cervical Cancers, Vulvar Cancer
Phase 1CompletedShanghai Bovax Biotechnology Co., Ltd.902018-10-102020-01-22
Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers
Durvalumab, Laboratory Biomarker Analysis, Stereotactic Radiosurgery - Advanced Cervical Adenocarcinoma, Advanced Vaginal Carcinoma
Phase 1CompletedM.D. Anderson Cancer Center202018-07-182023-09-13
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
XmAb20717 - Melanoma, Breast Carcinoma
Phase 1CompletedXencor, Inc.1502018-07-102022-12-01
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
Durvalumab, Tremelimumab, Radiation Therapy - Recurrent Gynecological Cancer, Metastatic Cervical Cancer
Phase 1TerminatedDana-Farber Cancer Institute162018-06-012025-05-31

Showing 20 of 36. Sign in to see all of them.

Narrower conditions

Uterine Cervical Neoplasms (32)  ·  Vaginal Neoplasms (25)  ·  Anus Neoplasms (17)  ·  Penile Neoplasms (15)  ·  Endometrial Neoplasms (14)  ·  Fallopian Tube Neoplasms (12)  ·  Carcinoma, Ovarian Epithelial (11)  ·  Breast Neoplasms (9)  ·  Neoplasms (9)  ·  Prostatic Neoplasms (9)  ·  Carcinoma, Hepatocellular (8)  ·  Squamous Cell Carcinoma of Head and Neck (8)  ·  Urinary Bladder Neoplasms (8)  ·  Bile Duct Neoplasms (7)

Broader conditions

Female Urogenital Diseases (36)  ·  Female Urogenital Diseases and Pregnancy Complications (36)  ·  Genital Diseases (36)  ·  Genital Diseases, Female (36)  ·  Urogenital Diseases (36)  ·  Genital Neoplasms, Female (35)  ·  Neoplasms by Site (35)  ·  Urogenital Neoplasms (35)  ·  Vulvar Diseases (34)  ·  Uterine Cervical Diseases (33)  ·  Uterine Diseases (33)  ·  Uterine Neoplasms (31)  ·  Neoplasms (27)  ·  Vaginal Diseases (25)  ·  Digestive System Diseases (24)

Interventions

Cyclophosphamide (4)  ·  fludarabine (4)  ·  Cisplatin (2)  ·  Docetaxel (2)  ·  Radiosurgery (2)  ·  Radiotherapy (2)  ·  Trastuzumab (2)  ·  aflibercept (2)  ·  aldesleukin (2)  ·  durvalumab (2)  ·  entinostat (2)  ·  tremelimumab (2)  ·  1,2-diaminocyclohexaneplatinum II citrate (1)  ·  3-aminopyridine-2-carboxaldehyde thiosemicarbazone (1)  ·  Acetaminophen (1)

Sponsors

National Cancer Institute (NCI) (6)  ·  HRYZ Biotech Co. (2)  ·  M.D. Anderson Cancer Center (2)  ·  Regeneron Pharmaceuticals (2)  ·  Sichuan Enray Pharmaceutical Sciences Company (2)  ·  Abramson Cancer Center at Penn Medicine (1)  ·  Alliance for Clinical Trials in Oncology (1)  ·  Beijing Health Guard Biotechnology, Inc (1)  ·  Case Comprehensive Cancer Center (1)  ·  Christian Hinrichs (1)  ·  Dana-Farber Cancer Institute (1)  ·  Gene Surgery LLC (1)  ·  Incyte Corporation (1)  ·  Marengo Therapeutics, Inc. (1)  ·  Masonic Cancer Center, University of Minnesota (1)

Countries

United States (21)  ·  China (8)  ·  Canada (2)  ·  France (1)  ·  Germany (1)  ·  Russia (1)  ·  South Korea (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Jian Zhang, Doctor (2)  ·  Lilie L Lin (2)  ·  William P. Tew, MD (2)  ·  Anthony W. Tolcher, MD (1)  ·  Barry L. Gause, MD (1)  ·  Charles Erlichman, MD (1)  ·  Charles Kunos (1)  ·  Christian S Hinrichs, MD (1)  ·  Daniel H. Sterman, MD (1)  ·  Franco M. Muggia, MD (1)  ·  Hoyoung M Maeng, M.D. (1)  ·  Irina Alekseenko (1)  ·  Leighton Elliott, MD (1)  ·  Levi S. Downs, MD (1)  ·  Martin King, MD, PhD (1)

Results publications

PMID 19949018, PMID 22002018, PMID 20068553, PMID 28596000, PMID 28744123, PMID 29186019, PMID 30184767, PMID 32510916, PMID 33558725, PMID 34766118, PMID 36399037, PMID 40273550, PMID 42249319, PMID 42816483

NIH funding

2023 (2), P30CA016087 (1), P30CA043703 (1), U01CA062502 (1), U01CA076576 (1), U01CA076642 (1)